76 related articles for article (PubMed ID: 21271216)
21. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
[TBL] [Abstract][Full Text] [Related]
22. Molecular cloning of doublesex and mab-3-related transcription factor 1, forkhead transcription factor gene 2, and two types of cytochrome P450 aromatase in Southern catfish and their possible roles in sex differentiation.
Liu Z; Wu F; Jiao B; Zhang X; Hu C; Huang B; Zhou L; Huang X; Wang Z; Zhang Y; Nagahama Y; Cheng CH; Wang D
J Endocrinol; 2007 Jul; 194(1):223-41. PubMed ID: 17592036
[TBL] [Abstract][Full Text] [Related]
23. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
Hilsenbeck SG; Osborne CK
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1049s-1055s. PubMed ID: 16467123
[TBL] [Abstract][Full Text] [Related]
24. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
25. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
[TBL] [Abstract][Full Text] [Related]
26. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
27. 17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer.
Källström AC; Salme R; Rydén L; Nordenskjöld B; Jönsson PE; Stål O
Eur J Cancer; 2010 Mar; 46(5):892-900. PubMed ID: 20060711
[TBL] [Abstract][Full Text] [Related]
28. Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
Jansson A; Delander L; Gunnarsson C; Fornander T; Skoog L; Nordenskjöld B; Stål O
Clin Cancer Res; 2009 May; 15(10):3610-6. PubMed ID: 19401349
[TBL] [Abstract][Full Text] [Related]
29. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
30. SIRT2: tumour suppressor or tumour promoter in operable breast cancer?
McGlynn LM; Zino S; MacDonald AI; Curle J; Reilly JE; Mohammed ZM; McMillan DC; Mallon E; Payne AP; Edwards J; Shiels PG
Eur J Cancer; 2014 Jan; 50(2):290-301. PubMed ID: 24183459
[TBL] [Abstract][Full Text] [Related]
31. FOXL2 activates P450 aromatase gene transcription: towards a better characterization of the early steps of mammalian ovarian development.
Pannetier M; Fabre S; Batista F; Kocer A; Renault L; Jolivet G; Mandon-Pépin B; Cotinot C; Veitia R; Pailhoux E
J Mol Endocrinol; 2006 Jun; 36(3):399-413. PubMed ID: 16720712
[TBL] [Abstract][Full Text] [Related]
32. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
33. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
[TBL] [Abstract][Full Text] [Related]
34. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
35. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
Span PN; Lindberg RL; Manders P; Tjan-Heijnen VC; Heuvel JJ; Beex LV; Sweep CG
J Pathol; 2004 Apr; 202(4):395-402. PubMed ID: 15095266
[TBL] [Abstract][Full Text] [Related]
36. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
37. Use of tamoxifen in pT1a-pT1b, pN0 breast cancer.
Livi L; Saieva C; Paiar F; Simontacchi G; Galardi A; De Luca Cardillo C; Mangoni M; Paoletti L; Ponticelli P; Biti GP
Eur J Surg Oncol; 2007 Apr; 33(3):271-5. PubMed ID: 16831531
[TBL] [Abstract][Full Text] [Related]
38. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells.
Tu SH; Chang CC; Chen CS; Tam KW; Wang YJ; Lee CH; Lin HW; Cheng TC; Huang CS; Chu JS; Shih NY; Chen LC; Leu SJ; Ho YS; Wu CH
Breast Cancer Res Treat; 2010 Jun; 121(3):539-53. PubMed ID: 19655245
[TBL] [Abstract][Full Text] [Related]
40. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]